

## PRESS RELEASE

### BRAIN and Autodisplay Biotech cooperate

Joint development of innovative screening systems on the basis of cellularly exposed human protein systems

Zwingenberg and Düsseldorf, December 06, 2011: The white biotechnology company BRAIN AG and Autodisplay Biotech GmbH have announced a co-operation to develop innovative cellular screening systems today. The strategic collaboration aims at using the benefits of the exposition of cosmetically relevant human target molecules on the surface of screening cells in the search for new cosmetic actives.

BRAIN cooperates with Autodisplay Biotech, a technological leader in bacterial surface expression of proteins, a move which perfectly complements BRAIN's own screening systems and thus strategically expands the company's technology platform.

For BRAIN the collaboration announced today represents another important milestone in its corporate strategy to intensify co-operation with technology companies in order to drive forward the research and development of novel cosmetic actives.

For Autodisplay Biotech co-operating with BRAIN paves the way for a consistent further development of its own technology. The use of the surface expression technology and its direct application constitutes a tailor-made solution for the identification of bioactives within the project.

Contact:

BzRzAzizN  
Biotechnology Research  
And Information Network AG  
Dr. Martin Langer  
Corporate Development  
Darmstädter Str. 34-36  
64673 Zwingenberg, Germany

Tel.: +49-(0)-6251-9331-16  
Fax.: +49-(0)-6251-9331-11  
E-Mail: [ml@brain-biotech.de](mailto:ml@brain-biotech.de)  
[www.brain-biotech.de](http://www.brain-biotech.de)

Autodisplay Biotech GmbH  
Dr. Ruth Maas, CEO  
Lifescience Center  
Merowinger Platz 1a  
D-40225 Düsseldorf Germany

Tel. +49 211 9945 9650  
Fax. +49 211 9945 9636  
Email: [ruth.maas@autodisplay-biotech.com](mailto:ruth.maas@autodisplay-biotech.com)  
[www.autodisplay-biotech.com](http://www.autodisplay-biotech.com)

“The co-operation with BRAIN once more proves that Autodisplay Biotech has successfully employed its technology in the past to build up a valid, industrially relevant screening system, opening up new opportunities for difficult-to-access targets in particular. Thanks to BRAIN’s internal resources - bioactives and natural substances - we can now quickly find and find new active ingredients and explained the methods of action,” says Dr. Ruth Maas, CEO of Autodisplay Biotech.

“This strategic co-operation helps us tap into an immense potential for synergy, which will make those human target molecules in particular accessible to an intensive BioActives screening which would not be accessible using traditional technologies,” explains Dr Jürgen Eck, Chief Scientific Officer of BRAIN AG. “Screenings for new modes of action, a core competency of white biotechnology, have been at the top of BRAIN’s agenda for many years as they offer an immense potential for growth. This is why we are looking very much forward to intensively using and jointly advancing the synergies resulting from the co-operation between the two companies.”

### About BRAIN

BRAIN AG is an industrial “white” biotech company which discovers and develops novel bio-active natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to the discovery and production of new biological compounds and biocatalysts, the company achieves creative solutions by harnessing nature’s untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. Since its foundation in 1993, BRAIN has entered into over 70 strategic collaborations with nearly all the relevant companies within the chemical industry as e.g. BASF, Ciba, Clariant, Evonik Degussa, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz, Schering, Südzucker and Symrise, to name but a few. Currently, BRAIN employs 99 highly skilled people.

For their groundbreaking industrial biotechnology activities for a sustainable „biologisation of the chemical industry“ using nature’s toolbox for industrial processes, BRAIN with its CEO Dr. Holger Zinke received the “Deutschen Umweltpreis 2008” of the “Deutsche Bundesstiftung Umwelt”, DBU.

[www.brain-biotech.de](http://www.brain-biotech.de)

### About Autodisplay Biotech

Autodisplay Biotech GmbH are technology leaders in bacterial surface expression. Using this technology, anything from simple peptides to complex proteins can be presented on the surfaces of bacteria and thus may be used to identify innovative products in the biocatalysis and bioanalytics fields of the chemicals and pharmaceuticals industry. Ever since its foundation as a spin-off from Düsseldorf’s Heinrich Heine University in 2008, Autodisplay Biotech’s founders Prof. Dr. Jose, Dr. Ruth Maas and Dr. Gunter Festel and their six employees have focussed on the consistent further development of their proprietary technology. This will permit the company to offer intelligent solution-oriented screening and production systems for the bio-based industry of tomorrow.

[www.autodisplay-biotech.com](http://www.autodisplay-biotech.com)

### Picture:



BRAIN Automated Screening Facilities: Using cellular based assays for high throughput screening for the identification of novel Cosmeceuticals.

© Kristian Barthen, Archive BRAIN AG, Zwingenberg –  
Reprint permitted with byline

### Picture and text

Both the picture and the text used in this press release may be downloaded at

[www.brain-biotech.de](http://www.brain-biotech.de), under the “News” header.